Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Begelomab
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Adienne
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD
Details : Begelomab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Graft vs Host Disease.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
April 08, 2015
Lead Product(s) : Begelomab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Adienne
Deal Size : Inapplicable
Deal Type : Inapplicable